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Background: Cardio-protective effect of fibrate therapy is controversial and current research is to evaluate the
effect of fenofibrate therapy on rats with hypertriglycemia.
Methods: Rats with hypertriglycemia were produced by 10% fructose administration (10 ml daily) for 4 weeks. After
model has been successfully produced as reflected by increased triglyceride level, different doses of fenofibrate,
namely low dose (50 mg/kg body weight) and high dose (100 mg/kg body weight), were orally prescribed for 2
weeks. At baseline, 4 weeks of fructose administration and 2 weeks of fenofibrate therapy, parameters of interest
were evaluated and compared.
Results: At baseline, no significant differences of parameter were observed between groups. After 4 weeks of
fructose prescription, triglyceride level increased in company with high density lipoprotein cholesterol (HDL-C) and
apoprotein A1 (ApoA1) decreased. C-reactive protein (CRP) and malondialdehyde (MDA) levels were also elevated.
Endothelial function was impaired as reflected by reduced nitric oxide (NO) production and elevated serum
asymmetric dimethylarginine (ADMA) level. All these changes were significant as compared to the control group
(P < 0.05), suggesting that short-term of triglyceride elevation could potently initiate atherosclerosis. With 2 weeks
of fenofibrate therapy, in comparison to un-treated group, triglyceride level was significantly reduced in parallel with
HDL-C and ApoA1 elevation. Inflammation and oxidation were also profoundly ameliorated as reflected by CRP and
MDA reduction. Notably, NO production was enhanced in company with serum ADMA level decrease. Overall, these
improvements manifested in a dose-dependent manner, which was supported by multivariate regression analysis
showing that after adjusted to other variables, the dose of fenofibrate therapy remained significantly associated
with NO production and serum ADMA level, with OR of 1.042 (high-dose versus low-dose, 95% CI 1.028-1.055,
P < 0.05).
Conclusions: Fenofibrate therapy not only could reduce triglyceride level but also confer pleiotropic effects in
terms of endothelium-protection and amelioration of inflammation and oxidation in a dose-dependent manner.
Keywords: Fibrate, Hypertriglycemia, Pleiotropic effectsIntroduction
Atherosclerotic cardiovascular disease (ASCVD) is the
leading cause of morbidity and mortality worldwide [1].
Dyslipidemia, predominantly featured by increased low
density lipoprotein cholesterol (LDL-C) level, is one of
the most important risk factors for ASCVD [2]. There-
fore, in the past decades, LDL-C has become the princi-
pal therapeutic target for reducing the incidence and
prevalence of ASCVD [3,4]. Nonetheless, despite target* Correspondence: cardiologyzcm@163.com; ffhuang18@163.com
†Equal contributors
Department of Cardiology, Tongji Hospital, Tongji University, Shanghai
200092, China
© 2015 Sun et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.LDL-C level has been achieved by statins therapy, re-
sidual cardiovascular risk still persists [5]. Recently, two
large clinical researches show that decreased fasting or
non-fasting triglyceride levels due to APOC3 gene loss-
of-function mutation is significantly associated with
reduced ischemic cardiovascular events, which is inde-
pendent of LDL-C reduction [6,7]. Therefore, it is rea-
sonable to postulate that increased triglyceride level
may at least partially contribute to the residual cardio-
vascular risk, if not at all [8]. However, whether there is
a causal relationship between triglyceride reduction and
cardiovascular events reduction is still inconclusive andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stood yet [9-11]. Previously, many epidemiological
studies show that no consistent cardio-protective ef-
fects could be obtained with triglyceride reduction by
fibrate therapy [5,12,13], a medicine specific for triglycer-
ide regulation.
With regard to the conflicting findings of previous re-
searches as well as recent emerging evidence suggesting
that reduced triglyceride level due to loss-of-function
mutation of APOC3 gene is associated with reduced is-
chemic cardiovascular risk, we conducted a basic pre-
liminary research using hypertriglycemia animal model
in order to investigate the relationship between triglycer-
ide and endothelial dysfunction, a hallmark of early stage
of atherosclerosis. In addition, the efficacy of fibrate on
triglyceride and endothelial function will also be evalu-
ated. We believed that results from our present study
would provide insights for better understanding the ef-
fects of triglyceride on atherosclerosis and ASCVD
development.
Methods
Animal preparation and research protocol
Forty male Sprague–Dawley (SD) rats weighing 200–220
g were used in present research, and studied protocol
was approved by the Ethic Committee of Tongji Hos-
pital, Tongji University, Shanghai. Briefly, 30 rats were
randomly selected for hypertriglycemia model establish-
ment by virtue of orally prescribing 10% fructose solu-
tion (10 ml per day) for totally 4 weeks. The other 10
rats used as the control group (CONT) were given nor-
mal saline (10 ml per day) for 4 weeks, too. Thereafter,
serum level of triglyceride was assessed to confirm
model successfully produced. Rats with hypertriglycemia
were then randomly and evenly assigned into 3 groups
as follows: low fenofibrate (LFF) group (50 mg/kg body
weight, p.o.), high fenofibrate (HFF) group (100 mg/kg
body weight, p.o.) and non-treated (NT) group. The dur-
ation of medical therapy was 2 weeks, and thereafter,
serum levels of lipid profiles and other parameters of
interest were evaluated.
Laboratory examination
At baseline and with 4 weeks of fructose administration,
fasting venous blood was collected for parameters of inter-
est evaluation. Biochemical parameters such as lipid pro-
files including triglyceride (TG), LDL-C, high density
lipoprotein cholesterol (HDL-C), total cholesterol (TC),
apoprotein A1 (ApoA1) and apoprotein B (ApoB), fasting
blood glucose (FBG) and liver enzymes involving alanine
aminotransferase (ALT) and aspartase aminotransferase
(AST) were concomitantly assessed by Automatic Bio-
chemistry Analyzer (Beckman coulter UniCel DxC 800
Synchron). Serum levels of inflammatory and oxidativemarkers such as C-reactive protein (CRP assay Kit, Nanjin
Jianchen Bioengineering Institute, H151) and malondial-
dehyde (MDA assay Kit, Nanjin Jianchen Bioengineering
Institute, A003-2) were assessed in accordance to the
manufacture’s instruction. Indicators of endothelial func-
tion including nitric oxide (NO) production (Total Nitric
Oxide Kit, Beyotime, Haimen, China, S0023) and serum
level of asymmetric dimethylarginine (ADMA, enzyme-
linking immune-absorbent assay kit, Shanghai Westan
Bio-technology Company) were also evaluated. After 2
weeks of fenofibrate therapy, parameters as mentioned
above were detected so as to define the effects of fenofi-
brate therapy on hypertriglycemia, endothelial function
and inflammation and oxidation.Statistical analyses
All continuous variables were expressed as mean ± SD,
and analyses were performed with SPSS software, ver-
sion 19.0 (SPSS Science, Chicago, IL, USA). Comparison
between each group was conducted by the Student’s t-
test when the data was normally distributed, otherwise
was compared by Wilcoxon rank-sum test. Multivariate
regression analysis was also conducted to evaluate the
relationship between the dose of fenofibrate and the
changes of endothelial function, and a value of P < 0.05
was considered statistically significant.Results
Parameters comparisons prior- and post-model
establishment
In order to evaluate the changes of lipid profiles, endo-
thelial functions and biomarkers of inflammation and
oxidation prior- and post-model establishment, serum
levels at baseline and after 4 weeks of fructose adminis-
tration were drawn. As shown in Table 1, parameters of
interest at baseline between each group were compar-
able. With 4 weeks of fructose administration, serum
level of triglyceride was significantly increased in com-
pany with decreased HDL-C and ApoA1 levels as com-
pared to the control group (P < 0.05). No prominent
changes of other lipids such as TC, LDL-C, and ApoB
were observed between groups. Serum levels of CRP and
MDA were profoundly elevated in parallel with trigly-
ceride elevation, suggesting that short-term of hypertri-
glycemia had robust effects on initiating systemic
inflammation and oxidation. Two sensitive and specific
biomarkers of endothelial function, named NO and
ADMA, correspondingly reduced in accordance to tri-
glyceride elevation as presented in Table 1, strongly indi-
cating that hypertriglycemia, independent of LDL-C
elevation, contributed to endothelial dysfunction. No sig-
nificant changes of FBG, ALT and AST were observed
between groups.
Table 1 Parameters comparisons prior- and post-model establishment
Variables CONT UT LFF HFF
Baseline
TG (mmol/L) 0.98 ± 0.10 0.96 ± 0.11 0.96 ± 0.12 0.99 ± 0.11
TC (mmol/L) 3.26 ± 0.17 3.27 ± 0.20 3.24 ± 0.14 3.27 ± 0.19
LDL-C (mmol/L) 1.99 ± 0.13 1.98 ± 0.12 1.99 ± 0.14 2.00 ± 0.16
HDL-C (mmol/L) 1.04 ± 0.05 1.05 ± 0.03 1.05 ± 0.04 1.05 ± 0.04
ApoA1 (mmol/L) 1.00 ± 0.03 1.00 ± 0.04 1.01 ± 0.02 1.01 ± 0.03
ApoB (mmol/L) 0.94 ± 0.05 0.94 ± 0.06 0.96 ± 0.03 0.95 ± 0.02
ALT (U/L) 28.5 ± 6.2 27.2 ± 3.9 25.8 ± 3.0 27.0 ± 2.3
AST (U/L) 29.6 ± 4.0 28.5 ± 3.7 27.3 ± 4.1 27.8 ± 4.0
FBG (mmol/L) 5.78 ± 0.13 5.85 ± 0.13 5.69 ± 0.14 5.90 ± 0.14
CRP (mg/L) 1.75 ± 0.23 1.77 ± 0.16 1.80 ± 0.15 1.75 ± 0.16
MDA(nmol/L) 0.98 ± 0.13 0.96 ± 0.10 0.99 ± 0.15 0.97 ± 0.14
NO (μmol/L) 14.16 ± 1.22 13.54 ± 1.09 13.87 ± 1.13 13.99 ± 1.15
ADMA (nmol/L) 69.24 ± 10.17 68.30 ± 10.28 67.15 ± 11.52 68.64 ± 12.08
4 weeks later
TG (mmol/L) 0.97 ± 0.12* 2.26 ± 0.36 2.29 ± 0.27 2.28 ± 0.20
TC (mmol/L) 3.28 ± 0.31 3.43 ± 0.41 3.40 ± 0.43 3.37 ± 0.38
LDL-C (mmol/L) 1.99 ± 0.15 2.02 ± 0.26 2.05 ± 0.33 2. 03 ± 0.22
HDL-C (mmol/L) 1.06 ± 0.05* 0.91 ± 0.03 0.90 ± 0.05 0.91 ± 0.03
ApoA1 (mmol/L) 1.02 ± 0.03* 0.86 ± 0.05 0.86 ± 0.04 0.88 ± 0.05
ApoB (mmol/L) 0.95 ± 0.04 0.98 ± 0.04 0.97 ± 0.03 0.98 ± 0.04
ALT (U/L) 26.7 ± 5.2 31.5 ± 4.2 30.6 ± 3.7 32.1 ± 4.4
AST (U/L) 28.7 ± 4.2 32.1 ± 3.0 32.0 ± 3.6 33.4 ± 4.2
FBG (mmol/L) 5.89 ± 0.16 6.04 ± 0.16 6.01 ± 0.10 6.03 ± 0.12
CRP (mg/L) 1.76 ± 0.11* 9.15 ± 1.07 9.39 ± 1.06 9.27 ± 1.06
MDA(nmol/L) 0.98 ± 0.14* 3.36 ± 0.40 3.47 ± 0.36 3.40 ± 0.47
NO (μmol/L) 13.87 ± 1.14* 9.24 ± 1.06 9.29 ± 1.04 9.37 ± 1.05
ADMA (nmol/L) 69.32 ± 11.31* 96.45 ± 13.35 99.36 ± 12.20 100.24 ± 11.61
Denote: *P < 0.05 versus other groups.
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fenofibrate therapy
In order to assess the effects of fenofribate therapy on
hypertriglycemia, endothelial function and systemic in-
flammation and oxidation, different doses of fenofibrate,
named low- and high-dose (LFF and HFF), were prescribed
for 2 weeks. As presented in Table 2, with 2 weeks of feno-
fibrate therapy, as compared to the un-treated (UT) group,
serum levels of TG, HDL-C and ApoA1 were improved in
both LFF and HFF groups. Serum levels of CRP and MDA
were gradually decreased in correspondence to the doses
of fenofibrate therapy. Notably, the improvements of NO
production and serum ADMA level were also presented in
a dose-dependent manner. All above improvements sug-
gested that the efficacy of fenofibrate therapy on hypertri-
glycemia, endothelial function, systemic inflammation and
oxidation was associated with the dose used.Relationship between the dose of fenofibrate and the
change of endothelial function
In order to investigate the relationship between the dose
of fenofibrate use and the changes of endothelial func-
tion, multivariate regression analysis was performed.
After adjusted to TC, LDL-C, HDL-C, TG, FBG, CRP
and MDA, the dose of fenofibrate therapy remained sig-
nificantly associated with NO production and serum
ADMA level, with OR of 1.042 (high-dose group versus
low-dose group, 95% CI 1.028-1.055, P < 0.05).
Discussion
The effects of hypertriglycemia on atherosclerosis and
ASCVD have been a controversial issue for decades [8,11].
Previously, some basic studies and observational clinical
researches show that increased triglyceride level contrib-
utes to the initiation and progression of atherosclerosis
Table 2 Parameters comparisons with different doses of fenofibrate therapy
Variables CONT UT LFF HFF
TG (mmol/L) 0.95 ± 0.06* 2.30 ± 0.40 2.18 ± 0.35 1.96 ± 0.24#
TC (mmol/L) 3.27 ± 0.25 3.31 ± 0.36 3.30 ± 0.24 3.28 ± 0.16
LDL-C (mmol/L) 1.99 ± 0.13 2.04 ± 0.16 2.01 ± 0.24 2.00 ± 0.21
HDL-C (mmol/L) 1.06 ± 0.04 0.90 ± 0.04 0.97 ± 0.05 1.03 ± 0.03#
ApoA1 (mmol/L) 1.03 ± 0.03 0.86 ± 0.04 0.92 ± 0.02 0.99 ± 0.05#
ApoB (mmol/L) 0.96 ± 0.05 0.98 ± 0.03 0.98 ± 0.04 0.98 ± 0.02
ALT (U/L) 27.5 ± 2.9 30.2 ± 1.6 29.0 ± 2.2 28.2 ± 1.5
AST (U/L) 28.4 ± 2.3 31.0 ± 2.5 29.5 ± 2.4 28.6 ± 1.0
FBG (mmol/L) 5.88 ± 0.15 6.04 ± 0.14 6.00 ± 0.13 6.00 ± 0.10
CRP (mg/L) 1.80 ± 0.13* 9.20 ± 1.04 9.09 ± 0.98 8.92 ± 0.76#
MDA(nmol/L) 0.98 ± 0.11* 3.35 ± 0.13 3.21 ± 0.16 3.03 ± 0.12#
NO(μmol/L) 13.21 ± 1.03* 9.16 ± 1.12 9.35 ± 1.08 9.98 ± 1.00#
ADMA (nmol/L) 68.24 ± 9.13* 97.33 ± 10.72 95.46 ± 10.33 91.25 ± 11.25#
Denote: *P < 0.05 versus other groups, #P < 0.05 versus the CONT group.
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als using fibrate, the potent triglyceride-modulation medi-
cine, show no consistent clinical benefits on reducing
cardiovascular events in spite of profound reduction of tri-
glyceride level [16,17]. Recently, two large clinical trials
demonstrate that decreased fasting or non-fasting trigly-
ceride level, owing to loss-of-function mutation of APOC3
gene, is independently associated with reduced ischemic
cardiovascular risk [6,7]. Of clinical relevance, our present
research also shows that as compared to the non-treated
group, triglyceride reduction by fenofibrate therapy results
in the improvement of endothelial function and systemic
inflammation and oxidation, and these changes are mani-
fested in a dose-dependent manner, suggesting that in the
early stage of atherosclerosis initiating by hypertriglyce-
mia, fenofibrate therapy may play a role on vascular-
protection.
Knowingly, LDL-C is the so-called bad cholesterol which
leads to prevalent atherosclerosis and ASCVD. Statins, a
specific cholesterol-modulation medicine, potently de-
creases LDL-C level and confers robust cardio-protective
effects. However, despite LDL-C level has been reduced to
less than 1.8 mmol/dL, a substantial number of patients
still have recurrent cardiovascular events which now rec-
ognized as residual cardiovascular risks [18,19]. Many risk
factors, such as lipoprotein (a) and lipoprotein-associated
phospholipase A2, have been identified responsible for the
residual cardiovascular risks as suggested by previous ob-
servational researches [20-24]. Whether increased trigly-
ceride level is accounted for the residual cardiovascular
risks is unclear yet, however. Evidence from two recent
large clinical researches suggested that the whole-life low
triglyceride level due to loss-of-function mutation of
APOC3 gene was independently associated with low car-
diovascular risk. While previous epidemiological researchesusing fibrate temporarily decreasing triglyceride level re-
sulted in contradictory outcomes. To our best knowledge,
it might be at least partially due to the following two
mechanisms. In the first place, the effect of whole-life low
triglyceride level on cardiovascular system was strikingly
and mechanically different from the transient low trigly-
ceride level derived from fibrate therapy. On the other
hand, benefits resulted from loss-of-function mutation of
APOC3 gene might not only ascribe to whole-life low tri-
glyceride level but might also be associated with other un-
explored mechanisms.
In order to reveal the effects of short-term hypertriglyce-
mia on atherosclerosis, as reflected on endothelial dys-
function, and to evaluate the efficacies of fenofibrate
treatment on endothelial function in the setting of hyper-
triglycemia, we conducted a preliminary basic research.
Results from our present research showed that short-term
of hypertriglycemia, produced by fructose administration,
rendered robust adverse effects on endothelium in rats, as
reflected by decreased NO production and increased
serum ADMA level. Mechanically [25,26], fasting triglyc-
erides are markers of remnant particles including very low
density lipoprotein cholesterol and intermediate density
lipoprotein cholesterol. Like LDL-C, these lipoprotein-rich
triglycerides are potential to penetrate endothelial barriers,
retain in arterial intima and cause atherosclerosis. Add-
itionally, promoting systemic inflammation and oxidation
owing to hypertriglycemia also accelerates atherosclerosis.
Therefore, preliminary data from our present research
supported the notion that increased triglyceride level was
at least partially accounted for the residual cardiovascular
risks, if not completely.
We then evaluated the efficacies of different doses of
fenofibrate therapy on hypertriglycemia, endothelial
function, and systemic inflammation and oxidation. As
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provided benefits in terms of triglyceride-reduction, in-
creased NO production and decreased ADMA level, as
well as decline of CRP and MDA levels. Overall, these
improvements manifested a dose-dependent manner
which was further supported from results by multivari-
ate regression analysis. After adjusted to lipid profiles,
CRP and MDA, the dose of fenofibrate therapy
remained significantly associated with NO production
and serum ADMA level, with OR of 1.042 (high-dose
group versus low-dose group, 95% CI 1.028-1.055, P <
0.05). Regarding the adverse effects of hypertriglycemia
on endothelium, we considered that triglyceride reduc-
tion might be the source of the upcoming benefits in
terms of prominent improvement of endothelium and
systemic inflammation and oxidation. Secondly, we ob-
served that with fenofibrate therapy, serum levels of
HDL-C and ApoA1 simultaneously elevated. As is well
known that, HDL-C is the good cholesterol which can
transport cholesterol from periphery to liver and then
excreting into intestinal tract [27]. Therefore, we con-
sidered that increased HDL-C and ApoA1 levels might
also be the underlying mechanism associated with the
benefits derived from fenofibrate therapy. Intriguingly
and importantly, since over-consumption of fat or
carbohydrate as animal-model established in our
present research is the main cause of hypertriglycemia,
it is possible that adding nutraceuticals or functional
food ingredients into fenofibrate therapy could confer
synergistic benefits on vascular system [28]. With re-
spect to the safety of fenofibrate therapy, we further
evaluated the liver enzymes which showed no signifi-
cant changes of ALT and AST after two weeks’ therapy
between groups.Conclusions
Results from our present preliminary research suggest that
increased triglyceride level may confer residual cardiovas-
cular risk mechanically, and fenofibrate therapy not only
could reduce triglyceride level but also could confer pleio-
tropic effects in terms of endothelium-protection and
amelioration of systemic inflammation and oxidation with
a dose-dependent manner.
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